Navigation Links
Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference

EXTON, Pa., Jan. 8 /PRNewswire/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that Nicholas L. Teti, Jr., Chairman, and Declan Daly, Chief Executive Officer of Isolagen, will present at the 26th Annual JPMorgan Healthcare Conference on Thursday, January 10, 2008 at 2:00 p.m. (Pacific Time) / 11:00 a.m. (Eastern Time). The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at An archive of the presentation will be available on the Company's website for 30 days following the conference.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.

SOURCE Isolagen(TM), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen Modifies Ongoing Clinical Program for Acne Scars
2. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
3. Isolagen, Inc. Postpones Annual Meeting
4. Emageon to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
6. Covance to Present at 26th Annual JPMorgan Healthcare Conference
7. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
8. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
9. DaVita Inc. to Present at JPMorgan Healthcare Conference
10. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: